Although the total number of men with testosterone deficiency is unknown, it has been estimated that up to 13 million men over 45 years of age in the U.S. may have symptoms associated with low testosterone.(1) Clinical trial data indicated that Axiron can restore blood concentration of testosterone within the normal range in most men.(2)
David Ricks, president, Lilly USA said, Lilly is proud to expand our focus in men’s health. The addition of Axiron to our product portfolio reinforces Lilly’s commitment to provide innovative treatment options for patients.
Dr. Richard Treagus, chief executive officer, Acrux said, The FDA approval is a major milestone for Axiron and for Acrux. After years of research, we are excited to partner with Lilly to provide this novel application method for men with low testosterone.